Abstract
Ocrelizumab is a high-efficacy disease modifying therapy (DMT) for patients with relapsing remitting multiple sclerosis (RRMS). To assess the socioeconomic value of ocrelizumab in RRMS compared with teriflunomide, dimethyl fumarate, and cladribine in Canada.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
